Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management

Inclusion Criteria:

1. Age 18 to 80 years (inclusive);

2. Patients with acute ischemic stroke;

3. Planned to receive intravenous thrombolysis within 4.5 hours of onset;

4. Elevated blood pressure: Before receiving intravenous thrombolysis treatment, bloodpressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes);

5. Informed consent signed (or signed by a proxy).

Exclusion Criteria:

1. Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage,intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epiduralhematoma).

2. History of intracranial hemorrhage; severe head trauma or stroke within the last 3months.

3. Intracranial tumors, giant intracranial aneurysms.

4. Intracranial or spinal surgery within the last 3 months; major surgery within thelast 2 weeks; arterial puncture at a site not easily compressed for hemostasiswithin the last 7 days.

5. Gastrointestinal or urinary system bleeding within the last 3 weeks.

6. Aortic dissection.

7. Acute bleeding tendency, including platelet count < 100×10^9/L or other bleedingtendencies.

8. Received low-molecular-weight heparin orally within 24 hours; taking warfarin withINR > 1.7 or PT > 15 seconds; used a new oral anticoagulant within 48 hours.

9. Blood glucose < 2.8 mmol/L or > 22.2 mmol/L.

10. Large area cerebral infarction indicated on head CT or MRI (infarction area > 1/3 ofthe middle cerebral artery territory).

11. Active visceral hemorrhage, known bleeding diathesis or significant bleedingdisorders within the past 6 months

12. Severe ischemic stroke (NIHSS score > 25)

13. Epileptic seizures at the time of stroke onset

14. Pregnant or lactating women

15. Various terminal diseases with an expected survival of ≤ 3 months

16. Any other physical conditions where the doctor deems participation in this study maybe detrimental to the patient

17. Currently participating in other drug or device clinical trials

18. mRS score > 2 before onset of the disease.